Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Trop Parasitol ; 11(1): 31-37, 2021.
Article in English | MEDLINE | ID: mdl-34195058

ABSTRACT

BACKGROUND: The emergence of widespread resistance of Plasmodium species to most antimalarial drugs has led to a more vigorous and concerted research on traditional medicinal plants for the treatment of malaria. OBJECTIVE OF STUDY: The study was aimed to investigate the in vitro antiplasmodial activity of crude ethanolic and aqueous extracts of Phyllanthus amarus against clinical isolates of Plasmodium falciparum in Northwestern Nigeria. MATERIALS AND METHODS: The plant was extracted using two solvents, water and ethanol, where a high yield was obtained from the aqueous extracts (11.9%) as compared to the ethanolic extract (9.64%). The extracts were evaluated in vitro at concentrations of 6.25, 12.5, 25, 50, and 100 µg/ml, and the level of potency in each case was expressed as the concentration of the extract that exhibited a 50% reduction of the parasites relative to control (100%) parasitemia. Artemether-lumefantrine was used as a positive standard in the assay. RESULTS: All extracts showed a significant reduction in parasite growth relative to control (P ≤ 0.05). Ethanolic extract exhibited a higher antiplasmodial activity of 76.8%, half-maximal inhibitory concentration (IC50) of 5.80 µg/ml, and aqueous extract had an activity of 75.3%, IC50 of 7.94 µg/ml. Both extracts exhibited very active antiplasmodial activity. Oral acute toxicity test in the doses of 500, 1000, and 1500 mg/kg showed no sign of toxicity on albino mice after 48 h. CONCLUSION: Although there was an increase in appetite after 24 and 48 h, the findings from this study show that P. amarus possesses a promising antimalarial activity which can be exploited for malaria therapy and justifies the traditional use of the plant in malaria treatment.

2.
J Immunoassay Immunochem ; 42(4): 380-392, 2021 Jul 04.
Article in English | MEDLINE | ID: mdl-33591885

ABSTRACT

Human Parvovirus B19 (B19 V) infection is hyperendemic in Nigeria. Pregnant women are not classically immunocompromised but maybe physiologically immunosuppressed and susceptible to viral infection. However, there is a paucity of studies on the epidemiology of B19V in Jigawa State, Northwestern Nigeria. This study aims to determine the seroprevalence, sociodemographic, and risk factors of human B19V infection among present women attending antenatal clinics of Jahun General Hospital, Nigeria. Between 2 February and 30 June 2019, blood samples were collected from 200 consented pregnant women and analyzed for anti-B19V IgM and IgG using commercially available enzyme-linked immunosorbent assay (ELISA). Sociodemographic and risk factors of subjects were collated through pre-tested structured questionnaires. Data generated were statistically analyzed for the association of anti-B19V and subjects' variables studied. Overall, the seroprevalence of anti-B19V IgM and IgG among pregnant women attending antenatal clinics of Jahun General Hospital, Nigeria was 6.0% and 22.5%, respectively. There was no significant association between the seroprevalence of anti-B19V IgM and anti-B19V IgG with all the sociodemographic variables and risk factors of pregnant women (P Ëƒ0.05). However, pregnant women with a history of blood transfusion had a significant risk associated with seroprevalence of B19V IgM (OR = 5.95; 95% CI: 1.96-22.76; P = .009). Findings from this study revealed that a high proportion of the pregnant women were susceptible to B19V infection and anti-B19V IgG immunity decreased with age. Given the incidence of acute B19V infection, it is clinically important to continuously monitor their erythrocytes indices and screen their neonates for B19V infection and fetal complications.


Subject(s)
Parvoviridae Infections/diagnosis , Parvovirus B19, Human/immunology , Adolescent , Adult , Cross-Sectional Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Nigeria/epidemiology , Parvoviridae Infections/immunology , Pregnancy , Risk Factors , Young Adult
3.
J Infect Dev Ctries ; 14(7): 691-695, 2020 07 31.
Article in English | MEDLINE | ID: mdl-32794455

ABSTRACT

As the incidence of Coronavirus Disease 19 (COVID-19) continues to rise, many countries have been seeking for medical assistance such as donation or procurement of laboratory test kits and strips. These consumables are largely intended for use in the laboratory investigations of COVID-19 cases, suspected contacts, asymptomatic persons and in discharging cured persons. Thus, this article was instigated to update and remind healthcare providers and policymakers (especially those in developing countries) on the principles of sample collections, storage, transportation, laboratory protocols and networks needed for appropriate public health response against COVID-19 pandemic in Africa and other developing countries. In addition, this article presents challenges that hinder adequate COVID-19 laboratory response and discuss some possible solutions that could ameliorate these constrains.


Subject(s)
Betacoronavirus , Clinical Laboratory Techniques/methods , Coronavirus Infections/diagnosis , Laboratories , Pneumonia, Viral/diagnosis , Specimen Handling , Africa/epidemiology , Betacoronavirus/chemistry , Betacoronavirus/genetics , Betacoronavirus/immunology , COVID-19 , COVID-19 Testing , Coronavirus Infections/epidemiology , Coronavirus Infections/virology , Epidemiological Monitoring , Humans , Pandemics , Pneumonia, Viral/epidemiology , Pneumonia, Viral/virology , Public Health , Reverse Transcriptase Polymerase Chain Reaction/methods , SARS-CoV-2 , Serologic Tests
4.
Pathog Glob Health ; 114(3): 111-116, 2020 05.
Article in English | MEDLINE | ID: mdl-32191166

ABSTRACT

Chikungunya (CHIK) is a re-emerging and myo-arthritogenic arboviral infection that has affected significant global population. However, CHIK is a neglected disease in Nigeria. This study aimed to estimate the pooled prevalence pattern of CHIK virus infection in Nigeria. A systematic review of eligible articles was conducted from "PubMed", "Scopus", "Google Scholar" and "Web of Science", between January 1980 to February 2020. Peer-reviewed articles describing CHIKV infection in cross-sectional studies were systematically reviewed. Random-effect model was used to pool the prevalence of CHIKV infection and associated sociodemographic data reported from eligible studies. In total, there were 10 published articles on CHIKV infection. Of these, 7 were cross-sectional studies, which comprised of 1347 pooled participants. The pooled anti-CHIKV IgM and IgG seroprevalence were 26.7% (95% CI: 23.2 - 30.4) and 29.3% (95% CI: 26.2 -32.6), respectively.  Of the pooled studies, there were 3.8% (95% CI: 2.0-6.4) CHIKV RNA positive cases and 46.1% prevalence of CHIKV neutralizing antibodies. Of the 6 geopolitical zones in Nigeria, Northeast had the highest serological evidence of CHIKV infection. There was a significance association between the prevalence of anti-CHIKV and geopolitical zones of Nigeria (χ²= 70.04; p˂0.0001). Sex (p ˂0.0001; OR= 1.87 [1.47 - 2.38]) and level of education (p ˂0.0001; OR= 2.74 [1.89 - 3.95]) were significant risk factors for pooled anti-CHIKV IgM seropositivity. However, no significant association was found with other sociodemographic variables (p ˃0.05). Although there was paucity of data on CHIKV research in Nigeria, this meta-analysis revealed a high prevalence of CHIKV infection in the country.


Subject(s)
Chikungunya Fever , Antibodies, Neutralizing/blood , Antibodies, Viral/blood , Chikungunya Fever/epidemiology , Chikungunya virus/immunology , Cross-Sectional Studies , Humans , Nigeria/epidemiology , Prevalence , Seroepidemiologic Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...